<DOC>
	<DOCNO>NCT00259558</DOCNO>
	<brief_summary>The purpose study find optimal dose retard release Phosphatidylcholine severe form ulcerative colitis . The hypothesis ulcerative colitis ( UC ) cause barrier dysfunction colonic mucus layer . The background study finding , phosphatidylcholine ( PC ) content colonic mucus strongly reduce UC compare healthy control patient CrohnÂ´s disease . The content meuasured non-inflamed area colon UC . Thus , evaluate whether substitution colonic PC effective method .</brief_summary>
	<brief_title>Dose Finding Study Retarded Phosphatidylcholine Pancolitis</brief_title>
	<detailed_description>Design : prospective , randomize , double-blind , dose-finding study retard phosphatidylcholine . Population : 10 patient per dose group ( 6 dos ) - 60 patient Remark : include historic group another study Inclusion criterion : Ulcerative Pancolitis chronic active course clinical index ( Rachmilewitz ) 7 , endoscopic index least 7 . No systemic steroid immunosuppressant since 4 week . Exclusion criterion : Pregnancy &amp; fulminant course</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>chronic active ulcerative pancolitis course 4 month clinical index rachmilewitz 7 endoskopic index 7 steroid last 4 week immunosuppressant last 4 week use topical klymsa pregnancy fulminant course infectious colitis</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Dose Finding</keyword>
	<keyword>Phosphatidylcholine</keyword>
</DOC>